Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Destiny Pharma
Biotech
Destiny seals C. diff therapy's phase 3 fate with Sebela
Destiny could be in line for $570 million thanks to a new development agreement with U.S.-based Sebela Pharmaceuticals for a C. difficile treatment.
Annalee Armstrong
Feb 24, 2023 10:10am
Biogen CEO steps down after Aduhelm blunder—Chutes & Ladders
May 6, 2022 9:30am
EuroBiotech Report—Cellectis, NuCana, Nightstar, Destiny and Verona
Sep 7, 2017 2:36pm
Destiny pulls off IPO to fund infection-prevention trial
Sep 5, 2017 9:10am
EuroBiotech: More Articles of Note
Aug 24, 2017 9:48am
Chutes & Ladders—Medivation founder Hung takes helm at Axovant
Apr 13, 2017 3:11pm